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ABSTRACT We previously demonstrated that the pri­
mary region of factor IX and IXa responsible for saturable 
specific binding to bovine aortic endothelial cells resides in 
residues 3-11 at the amino terminus of factor IX. We also 
demonstrated that mutations of lysine to alanine at residue 5, 
factor IX K5A, or valine to lysine at residue 10, factor IX V10K, 
resulted in a molecule unable to bind to endothelial cells. 
Moreover, a mutation with lysine to arginine at residue 5, 
factor IX K5R, resulted in a factor IX molecule with increased 
affinity for the endothelial cell binding site. In this paper we 
report that collagen IV is a strong candidate for the factor IX 
binding site on endothelial cells. Factor IX and factor IX K5R 
compete with 125I-labeled factor IX for binding to tetrameric 
collagen IV immobilized on microtiter plates, while factor X, 
factor VII, and factor IX K5A or V10K fail to compete. The Ka 
for wild-type factor IX binding to collagen IV in the presence 
of heparin was 6.8 ±  2 nM, and the Jfa for factor IX K5R was
1.1 ± 0.2 nM, which agrees well with our previously published 
Kd values of 7.4 and 2.4 nM for binding of the same proteins 
to endothelial cells. Our working assumption is that we have 
identified the endothelial cell binding site and that it is 
collagen IV. Its physiological relevance remains to be deter­
mined.
Factor IX is the zymogen of a serine protease which is active 
in normal hemostasis. Mutations in factor IX result in the 
bleeding disease hemophilia B. Factor IX is activated by factor 
XIa or factor Vlla-tissue factor to yield factor IXa; this 
reaction results from cleavage between residues 145/146 and 
180/181 of the factor IX. Activated factor IX, together with its 
nonenzymatic cofactor factor Villa, cleaves factor X to factor 
Xa. Factor IX, like factors X and VII, is a vitamin K-dependent 
clotting factor which contains multiple 4-carboxyglutamic acid 
(Gla) residues at its amino terminus. The factor IX Gla domain 
is followed by two epidermal growth factor-like domains, an 
activation peptide, and a serine protease domain. For a recent 
review see Roberts (1).
The binding of factor IX to a specific saturable site on 
endothelial cells was first described by Heimark et al. (2) and 
Stern et al. (3). Heimark et al. found that bovine endothelial 
cells had approximately 280,000 sites per cell with a Kd for 
factor IX of about 5 nM. The factor IX binding sites on the 
endothelial cell were subsequently characterized in great detail 
by Stern et al (4). They reported about 40,000 sites per cell and 
a K& for factor IX or IXa of about 2 nM. Moreover, it was found 
that factor IXa in the presence of factor VIII and factor X 
binds with a 10-fold increased affinity. The factor X-cleaving 
(“tenase”) complex on endothelial cells could catalyze the 
formation of factor Xa with a greater than a tenase
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complex assembled upon phospholipids. Finally, Brinkman et 
al (5) showed that the endothelium may serve as an effective 
surface for formation of a tenase complex.
We (6 ) determined that the primary region of factor IX and 
IXa responsible for binding to bovine aortic endothelial cells 
resides in residues 3-11 at the amino terminus of factor IX. We 
also demonstrated that mutations of lysine to alanine at 
residue 5, factor IX K5A, or valine to lysine at residue 10, factor 
IX V10K, result in a molecule unable to bind to endothelial 
cells. Moreover, a mutation of lysine to arginine at residue 5, 
factor IX K5R, results in a factor IX molecule that has a 3-fold 
increased affinity for the endothelial cell binding site. Our 
observation that factor IX residues 3-11 are critical for the 
factor IX endothelial cell interaction have recently been 
confirmed by Castellino’s laboratory (7). They demonstrated 
that converting the first 11 amino acids of protein C to those 
of factor IX resulted in a protein C chimera that bound to 
endothelial cells.
In an attempt to identify the molecule on bovine aortic 
endothelial cells to which factor IX was binding, Rimon et al 
(8) cross-linked factor IX to a 140-kDa protein on the surface 
of endothelial cells. In spite of this initial success, a number of 
laboratories have failed to identify the molecule to which factor 
IX binds, probably because the cross-linked factor IX was 
bound to a proteolytic fragment of collagen IV.
In this paper we report that collagen IV is a strong candidate 
for the factor IX binding site on endothelial cells. Collagen IV 
is an extracellular matrix (ECM) protein which is one of the 
major components of the basement membrane of endothelial 
cells (9,10). It is found arranged in a two-dimensional array in 
the lamina densa of basement membranes and is usually 
isolated from placenta (11) or the mouse tumor cell line EHS
(12). The isolation includes a limited pepsin digestion which 
leads to a significant fraction of tetrameric collagen. Tet­
rameric collagen IV is composed of four triple-helix collagen 
molecules joined by their amino-terminal 7S globular domains
(13). The triple-helical molecule, which consists of two al 
chains and one a l  chain, constitutes the collagen-like domain 
of collagen IV. The collagenous domain of collagen IV differs 
from fibrillar collagens in that its Gly-Xaa-Yaa sequence is 
interrupted by noncollagen-type sequences. Therefore the 
triple helix is not in perfect register, a condition which appears 
to provide flexibility for supercoiling of triple helices. More­
over, collagen IV has noncollagenous domains at both the 
amino and carboxyl termini of its constituent polypeptide 
chains.
Collagen IV may also be extracted by limited cleavage with 
collagenase to yield dimeric collagen. Dimeric collagen is 
composed of two triple-helical collagen molecules which are 
attached at their carboxyl termini by their NCI domains and
Abbreviations: ECM, extracellular matrix; EHS, Eneelbreth-Holm- 
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which lack the 7S domain (14). A cyanogcn bromide fragment 
from the triple-helical region of collagen IV (15,16) possesses 
high-affinity binding sites for alfil  and «2/31 integrins. The 
major collagen-binding integrin of platelets (17) is gp Ia/IIa, 
which is a synonym for alfil.
We report here that the triple-helical region of collagen IV 
possesses all of the attributes previously described for the 
factor IX binding site on endothelial cells.
M ATERIALS AND M ETHODS
Materials. Dulbecco’s modified Eagle’s medium (DMEM), 
DMEM/F12, fetal bovine serum, and porcine intestinal mu­
cosa heparin were from GIBCO/BRL. Removable microtiter 
wells were from Coming. lodobeads were from Pierce. Sodium 
deoxycholate was from Merck.
Bovine aortic endothelial cells were gifts from Charles 
Esmon and Naomi Esmon of the Oklahoma Medical Research 
Foundation (Oklahoma City, OK). Human plasma factor IX, 
factor IXa, factor X, factor VII, and thrombin were from 
Enzyme Research Laboratories (South Bend, IN). Factor VIII 
(Recombinate) was from Baxter Laboratories (Glendale, CA). 
Spectrozyme Xa was from American Diagnostica (Greenwich, 
CT). Recombinant wild-type factor IX and mutated factor IX 
were expressed and purified as previously described (6).
Human fibronectin and bovine collagen I (from Collagen 
Corp., Palo Alto, CA) were gifts from Staffan Johansson of the 
Department of Medical and Physiological Chemistry, Uppsala 
University, Sweden. Mouse laminin was from Rupert Timpl of 
the Max-Planck-Institut fur Biochemie, Germany. Recombi­
nant mouse entaclin was from Upstate Biotechnology (Lake 
Placid, NY). Heparan sulfate proteoglycan (HSPG) and lath- 
yritic collagen IV isolated from Engelbreth-Holm-Swarm 
(EHS) mouse sarcoma and human placenta collagen type V 
were from Becton Dickinson (Bedford, MA). Tetrameric (18), 
or dimeric (14) collagen, or the 7S domain (19) and cyanogen 
bromide fragment (CB3) of human placenta collagen IV (16) 
were prepared as described in the referenced papers. A 
different form of dimeric collagen IV, composed of truncated 
a l  and a l  chains from bovine testes basement membrane, was 
prepared as described (2 0 ) for lens capsule basement mem­
brane and was characterized by electron microscopy, SDS/ 
PAGE, and Western blotting (T. Kahsai and B.G.H., unpub­
lished results). Recombinant collagenase, and human collag- 
ens types I, III, IV, and V were purchased from Sigma. Rabbit 
anti-human collagen IV polyclonal antibody was from Chemi- 
con.
Binding of Factor IX to ECM. Bovine endothelial cells were 
grown in 48-well plates in DMEM containing 10% fetal bovine 
serum. Confluent cell monolayers were solubilized by treating 
three times for '10 min each with 0.5% sodium deoxycholate/ 10 
mM Tris-HCl/l mM phenylmethylsulfonyl fluoride, pH 8 . This 
was followed by washing the remaining ECM three times with 
2 mM Tris-HCl/l mM phenylmethylsulfonyl fluoride, pH 8 
(21). Binding experiments were done by using 0.5 nM 125I- 
labeled factor IX (125I-factor X) and 200-fold excess (100 nM) 
unlabeled proteins. Competition binding of factor IX with 
other ligands to intact bovine endothelial cells was as described 
(6).
Binding of Factor IX to Collagen Type IV. Lyophilized 
collagen IV was dissolved to 3 mg/ml in TBS (10 mM 
Tris-HCl/150 mM NaCl/ 2  mM CaCl2/ l  mM MgCl2, pH 8) and 
then diluted to 50 ¡jlg/ml. Removable wells were coated with
0.1 ml of this solution at 4°C overnight. The wells were washed 
three times with TBS and blocked with 3% ovalbumin for 3 hr 
at room temperature. Ninety microliters of various concen­
trations of unlabeled factor IX (or other competitors) in the 
presence (1 jag/ml) or absence of heparin was then added to 
each well. Ten microliters of I25I-factor IX (final 0.5 nM) was 
added to the wells and incubated at 4°C for 2.5 hr; the wells
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were then washed six times and bound radioactive material was 
measured in a y counter (Packard). Other ECM proteins were 
used to coat the wells as described above and tested for binding 
with factor IX.
Heat Denaturation and Sensitivity to Dithiothreitol. To test 
for the dependency of factor IX binding to the triple-helical 
conformation of collagen IV, tetramcric type IV collagen was 
denatured by heating at 60°C for 30 min and/or treatment with 
10 mM dithiothreitol before coating. The binding study was 
conducted as described above by incubating 0.5 nM 125I-factor 
IX with a 200-fold excess of unlabeled factor IX.
Elimination of Factor IX Binding to Collagen IV by Colla- 
genase Treatment. Five micrograms of human placental col­
lagen IV in 100 jtd was added to each well of a 96-well 
microtiter plate and incubated at 4°C overnight. After three 
washes with TBS, the coatings in some wells were digested with 
2.5 jxg of recombinant collagenase-I in 100 ¡A of TBS con­
taining 2 mM CaCh, 1 mM MgC^, and 0.2% BSA at 37°C for
2 hr. After three additional washes with TBS, binding exper­
iments were performed at 4°C for 2.5 hr as described above.
Factor X Activation on Endothelial Cells and ECMs. Con­
fluent bovine endothelial cells were seeded at 1.5 x 10s cells 
per well and grown in 24-well plates for 2 days. The ECM of 
endothelial cells was prepared as described above by removing 
the cells with 0.5% deoxycholate. Factor IXa (0.5 nM) was 
incubated with intact endothelial cells and ECM as in a binding 
experiment, and the tenase activity was measured on both the 
matrix and washed cells. The reaction was started by the 
addition of 400 /xl of a solution containing 5 units/ml factor 
Villa and 0.2 ¡M  factor X in 5 mM Tris-HCl/140 mM NaCI/2 
mM CaCl2/ 0 .2 % BSA, pH 7.5, Factor VIII was preactivated 
with thrombin at 37°C for 5 min and stored on ice until use. 
Aliquots (40 ¡A) were collected at timed intervals over 25 min. 
Each aliquot was added to a well of a 96-well microtiter plate
containing 60 ¡A of 50 mM Tris-HCl/175 mM NaCL/ 6  mM 
EDTA/0.05% ovalbumin, pH 7.5. Factor Xa activity was 
assayed by adding 100 /xl of 0.2 mM chromogenic substrate, 
Spectrozyme Xa, and the absorbance at 405 nm was monitored 
with a plate reader (Labsystems, Chicago) for 3 min at room 
temperature.
RESULTS AND DISCUSSION
Our initial stimulus to examine the role of the ECM in factor 
IX binding arose from the observation that heparan sulfate 
and heparin affected the binding of factor IX to endothelial 
cells. To examine the possible role of the ECM in factor IX 
binding, endothelial cells were removed by exposure to 0.5% 
sodium deoxycholate as described in Materials and Methods. 
Fig. 1 demonstrates that, at the time of measurement, 2 days, 
more factor IX binding sites are on the matrix than on intact 
endothelial cells. When the cells reach confluence, however, 
the situation is reversed. Therefore, although this experiment 
clearly demonstrates that the ECM binds factor IX, it is likely 
that collagen IV or an epitope of collagen IV is also present 
on the surface of endothelial cells. To examine if the ECM 
maintained the same specificity as that observed previously for 
endothelial cells we demonstrated that plasma factor IX or 
factor IX K5R competed for binding, while factor IX with the 
point mutations previously shown to lack the ability to bind 
endothelial cells (6) failed to compete (Fig. 2).
This observation suggests that the binding site that we have 
previously characterized on endothelial cells is actually found 
in the ECM secreted by endothelial cells. We therefore tested 
a number of known ECM proteins for their ability to bind 
factor IX. Human fibronectin, mouse laminin, mouse entactin 
(nidogen), mouse heparan sulfate proteoglycan, and both 
human and bovine collagens I, III, and V were tested; all failed 
to bind factor IX (Table 1),
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Intact Cell Monolayer ExtrmceUuUr Matrix
F i g . 1. Binding of i25I-factor IX to intact endothelial cell mono­
layers or to ECM at 24 hr after seeding. Tntact monolayers were used 
directly or the cells were removed by treating three times, for 10 min 
each, with 0.5% deoxycholate/10 mM Tris’HCl/1 mM phenylmeth- 
ylsulfonyl fluoride, pH 8, to remove cells. The remaining ECM was 
washed three times with 2 mM Tris*HCl/l mM phenylmethylsulfonyl 
fluoride, pH 8. Binding experiments were done on both the intact cells 
and the remaining ECM.
In the absence of heparin, factor IX bound to collagen IV, 
although with lower affinity (Xj = 43 nM) than to the ECM; 
in the presence of heparin at 1 jxg/ml, however, collagen IV 
bound with an affinity similar to that previously determined 
for endothelial cells (4, 6 ). Therefore, heparin was used in all 
subsequent experiments. Fig. 3 shows that theiid for wild-type 
factor IX binding to collagen IV in the presence of heparin was 
6.8 ± 2 nM and the Kd for factor IX K5R was 1.1 ± 0 .2  nM. 
These values agree well with our previously published Ka 
values of 7.4 and 2.4 nM for binding of the same factor IX 
variants to endothelial cells (6 ). The Kd values were obtained 
by analyzing three independent experiments simultaneously by 
the program m k  model (Biosoft, Ferguson, MO). There are 
uncertainties in the determination of the values because the 
concentration of competitor was frequently insufficient to 
allow the program to predict the nonspecific background. 
Therefore, the nonspecific value calculated for the factor IX 
IC5R mutant, which did reach a plateau, was used as a constant 
value for those experiments.
To determine if the specificity of binding observed with the 
ECM was retained with the purified collagen IV, competition 
experiments with wild-type and variant factor IXs were done. 
Fig.4 shows that factor IX and factor IX K5R compete with













None wt FIX PDCK5R FIXK5A FIX VIOK FIX 9-11
Competitor (200-fold excess)
Fig. 2 . Specificity of factor IX binding to the ECM. Confluent 
bovine endothelial cells were treated as described in the legend to Fig.
1 to remove cells. The remaining ECM was washed three times with
2 mM Tris*HCl/l mM phenylmethylsulfonyl fluoride, pH 8, and the 
specificity of the binding was determined. FIX, factor IX; wt, wild- 
type; FIX 9-11, residues 9-11, Phe-Val-Gln, changed to those of factor 
X, Met-Lys-Lys,





EI-IS cell heparan sulfate proteoglycan No
Bovine collagen I No
Human collagen V No
Lathyritic mouse EHS collagen IV No
Human placental collagen IV tetramer (Kuhn) Yes
Fluman placental collagen IV dimer (Kuhn) Yes
Human placental collagen IV 7S domain (Kuhn) No
Human placental collagen IV CNBr fragment
(binds to oil/31 and <*2/3 i integrins) (Kuhn) No
Human placental collagen IV (Sigma) Yes
The major known constituents of the ECM were coated 




125I-factor IX for binding to tetrameric collagen IV immobi­
lized on microtiter plates, whereas factor X, factor VII, and 
factor IX K5A or V10K fail to compete. The relative specificity 
is exactly that observed for endothelial cells (6 ).
To further examine the interaction between collagen IV and 
factor IX, monolayers of endothelial cells were incubated with 
0.5 nM 125I-factor IX and the competition was done with 
dimeric or tetrameric collagen IV instead of nonradioactive 
factor IX. The results for dimeric and tetrameric collagen were 
similar. Therefore, all four sets of data were analyzed simul­
taneously by the MK model, and a Kk\ value of 36 nM was 
obtained (see Fig. 5). This K<\ value approximates the 
determined for factor IX’s binding to collagen IV in the 
absence of heparin. Therefore, these results appear to confirm 
the role of collagen IV in binding to endothelial cells.
Collagen IV can be dissected into several fragments. Neither 
the amino-terminal 7S globular domain nor the carboxyl- 
terminal noncollagenous domain one (NCI) competed with
0.035
0.030 •  Competition by WT FIX, K d-6J  nM
0.025 - Competition By 
K5R,Kd-1.1nM
3c 0.020 -
0.015 -2  
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Log FIX Competitor (nM)
 ^ F i g . 3. Competition of factor IX or factor IX K5 R for binding of 
125I-factor IX to collagen IV. Binding wavs done by incubating 0.5 nM 
125I-factor IX and various concentrations of plasma factor IX as 
competitor for 2.5 hr at 4°C. Heparin was included in the binding 
buffer at 1 ¡ig/ml. After six washes with cold incubation buffer, the 
individual wells were counted. In this case the values obtained for 
binding to tetrameric collagen IV are almost identical to those 
obtained previously with intact endothelial cells.
Spedfidty of FIX Binding to Tetra meric Human Placental Collagen IV
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Fig. 4. Specificity of factor IX binding to tetrameric collagen IV. 
Two independent experiments arc separated by a space. Lyophilized 
tetrameric collagen IV was dissolved to 3 mg/ml in 10 mM Tris-HCl/ 
150 mM NaCl/2 mM CaCh/1  mM MgCl2, pH 8, then diluted to 50 
jug/ml. One hundred microliters of this solution was incubated at 4°C 
overnight in 06-well microtiter plates, blocked with ovalbumin, and 
used for binding studies.
endothelial cells for binding to factor IX (Table 1); moreover, 
both dimeric and tetrameric collagen bind 125I-factor IX. 
Because dimeric collagen IV lacks the 7S domain while 
tetrameric collagen IV lacks the NCI domain, this provides 
additional positive data that the binding site resides in the 
collagenous domain of collagen IV. The collagenous domain 
of collagen IV can be cleaved with cyanogen bromide to give 
several fragments. One of these, designated CB3, has been 
shown to bind the integrins a 1/31 and ¿*2/31 (16). The integrin 
a.2/31 is also known as glycoprotein la/IIa, which is a major 
platelet integrin. Patients with a defect in cv2/31 are impaired 
in collagen-stinYulated platelet aggregation (22). Furthermore, 
monoclonal antibodies against « 2 0 1  inhibit specifically the 












Concentration of Colagon IV (nM)
Fig. 5. Competition by collagen IV for factor IX binding to 
endothelial cells. In this experiment collagen IV was used as a 
competitor lor the binding of 125I-faclor IX to intact endothelial cell 
monolayers. Heparin was not included and the methods are as 


















F ig , 6 . Treatment of collagen IV with recombinant collagenase 
eliminates binding of ,2sI-factor IX. Collagen IV was applied to 
microtiter plates and a portion of the wells were treated with recom­
binant collagenase from Sigma. Treatment was with 2.5 ¡¿g of colla- 
genasc at 37°C for 2 hr.
the binding site for factor IX does not appear to reside in 
fragment CB3 of collagen IV (Table 1), it is interesting that 
factor IX and platelets both have binding sites on this prevalent 
ECM protein.
It is always difficult to prove that the binding one observes 
is not the result of some minor contaminating protein. How­
ever, several lines of evidence point toward collagen IV as the 
molecule to which factor IX binds. First, a polyclonal antibody 
to collagen IV inhibited the binding of 125I-factor IX (data not 
shown). Second, recombinant collagenase treatment of the 
purified collagen IV totally eliminated binding (Fig. 6 ). We 
also treated endothelial cells directly with collagenase and 
found that factor IX binding was reduced to nearly background 
levels. More severe treatment of ceils with collagenase would 
result in their release from the plates. Third, collagen IV from 
several different sources—for example, dimeric or tetrameric 
collagen IV prepared from human placenta or bovine testes— 
bound factor IX specifically. Finally, none of the other major 
constituents of the ECM bind factor IX (Table 1). This 
suggests that it is not an expected contaminant to which factor 
IX is binding,
The evidence that factor IX is not binding to a phospholipid 
membrane contaminant is shown in Fig. 7. Either heat déna­
turation or treatment with 10 mM dithiothreitol results in loss 
of binding of factor IX to collagen IV; this result is consistent 
with our failure to obtain positive results with ligand blotting 
experiments. Furthermore, we have found that mutant factor 
IX K5A or V10K binds phospholipid membranes normally (.Kj 
= 1.5 and 0.5 /xM, respectively) while failing to compete with






03 No Cold FIX 
M 100 nM Cold FIX
None H tit  &Q C 10 mM DTT 10 mM DTT 
60*C
Fig. 7. Heat denaturation or dithiothreitol (DTT) treatment of 
tetrameric collagen IV eliminates the binding of l25I-factor IX. The 
experiments were accomplished as described in the legend to Fig. 4.
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125l-factor IX for binding to endothelial cells (unpublished 
results).
When the ability of the ECM of bovine endothelial cells to 
function as a surface for tenase activity is compared with that 
of endothelial cells perse it is found that there is essentially no 
tenase activity on the ECM (Fig. 8 ), while the level of tenase 
activity on intact endothelial cells is similar to that observed by 
others (4, 5) (about 8 nmol of factor Xa generated per min). 
While these experiments are qualitative, it is clear that the 
activity of the matrix is much diminished compared with intact 
endothelial cells; this may simply reflect the need of a coop­
erative effect for phospholipid. Preliminary experiments from 
several industrial laboratories suggest that, while phospholip­
ids do stimulate activity in the presence of collagen IV, the 
stimulation does not exceed that of phospholipid alone.
At present it is difficult to assess the functional significance 
of these observations. Briet (25) reported that more infused 
factor IX could be recovered from CRM* than from CRM“ 
patients (CRM, cross-reacting material). lie  did mixing ex­
periments to demonstrate that the cellular components did not 
bind the infused factor IX and postulated that the endothelial 
cell lining of the blood vessel was the surface to which the 
infused factor IX was adsorbed. Therefore it is possible that 
collagen IV functions merely as a storage site and is the 
“extravascular space” where infused factor IX disappears. This 
scenario would, at a minimum, put the factor IX where it is 
needed upon rupture of a vessel.
In retrospect it is perhaps not surprising that collagen IV 
appears to be the factor IX binding site. Collagen IV is the 
major ECM protein, and one would expect coagulation to 
proceed after endothelial cell disruption rather than on the 
endothelial cell surface. Several collagens have been shown to 
activate platelets (26, 27), and there are a number of experi­
ments implicating the ECM in coagulation (26). Moreover, 
leech and tick anticoagulants that act by inhibiting the inter­
action between collagen and platelets have been identified (28, 
29). The interactions are complex and are not restricted to 
collagen IV; however, the leech anticoagulant protein does 
inhibit the binding of platelets to collagen IV (30). Collagen 












F ig . 8. Tenase activity of factor IX bound to collagen IV of ECM 
or intact endothelial cells. Factor IXa (final 0.5 nM) was bound to 
endothelial cells or matrix for 3 hr and washed six times as described 
in the text. The reaction was started by the addition of 400 ¡x\ of a 
solution containing 5 units/ml factor Villa and 0.2 /xM factor X in 5 
mM Tris*HCl/140 mM NaCl/2 mM CaCl2/0.2% BSA, pH 7.5. Ali­
quots (40 /ul) were collected at timed intervals over 25 min. Each 
aliquot was added to a well of a 96-well microtiter plate containing 60 
/x 1 of 50 mMTris’HCl/175 mM NaCl/6 mMEDTA/0.05% ovalbumin, 
pH 7.5. Factor Xa activity was assayed by adding 100 jud of 0.2 mM 
chromogenic substrate, Spectrozyme Xa, and the absorbance at 405 
nm was monitored with a plate reader (Labsystems) for 3 min at room 
temperature. A, Tenase activity on endothelial cells; M, tenase activity 
on the ECM.
structural alterations (31). Another coagulation-related ligand 
which binds with high affinity to collagen IV is protease 
nexin-1, which binds specifically to collagen IV with a Afd of 
approximately 15 nM (32). This interaction decreases protease 
nexin-l’s rate constant for the inhibition of urokinase or 
plasmin.
Because collagen IV appears to have so many properties 
identical with those of the previously characterized factor IX 
binding site-—that is, the K ti is nearly identical, the specificity 
of mutant factor IX is identical, and factor IX and IXa bind 
indistiguishably—it seems highly probable that collagen IV is 
the factor IX endothelial cell binding site that we have 
previously characterized. However, we cannot eliminate the 
possibility that there is yet another binding site for factor IX 
that resides upon the endothelial cell surface, that has different 
binding specificity, and that is responsible for the observed 
tenase activity of endothelial cells.
One aspect of our work is in contradiction to the results of 
Rimon et a l  (8), who reported that there was no binding to the 
plates after cells had been removed by the detergents CHAPS 
or Triton X-100. In our hands removing cells with either 
detergent results in a surface with specific factor IX binding 
activity. In addition, they reported that the binding specificity 
was maintained by proteins in the cellular extracts. We also 
observed that partially purified endothelial cell membranes 
adsorbed to microtiter plates resulted in a factor IX binding 
surface. We made large-scale membrane preparations from a 
bovine placenta but found that, while there was binding 
activity, there was no discrimination between factors IX, X, 
and VII. These differences remain unexplained.
The observation that collagen IV has a specific binding site 
for factor IX demands a host of additional physiological and 
biochemical experiments on the interaction between factor IX 
and the ECM as well as factor IX and collagen IV, Further­
more, it may be profitable to look at the effect of collagen IV 
on other blood coagulation factors.
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